U.S. Consumer Durables Stock News

Recent performance and context Cintas (CTAS) has been treading water lately, with the stock roughly flat over the past week and month, and still down about 7 % in the past 3 months. See our latest analysis for Cintas. Zooming out, Cintas still sits near all time highs, with a modest year to date share price return that suggests momentum has cooled a bit, even as long term total shareholder returns remain strong. If Cintas has you thinking about steady compounders, this could be a good moment...

Wondering if NIO at around $5 is a beaten down bargain or a value trap? You are not alone, and this breakdown will help you see where the upside and risks really sit. Despite being up 10.5% year to date and 11.5% over the last year, the stock has slid 22.0% in the last 30 days and is almost flat over the past week, a pattern that hints at shifting sentiment and uncertainty around the story. Recent headlines have focused on NIO's ongoing push to expand its EV lineup and partnerships around...

Johnson Outdoors (JOUT) just closed FY 2025 with fourth quarter revenue of about $135.8 million and basic EPS of roughly -$2.83, alongside a trailing twelve month revenue base of about $592.4 million and basic EPS of around -$3.34. The company has seen quarterly revenue move from about $105.9 million in Q4 2024 to $135.8 million in Q4 2025, while quarterly EPS shifted from roughly -$3.35 to -$2.83 over the same period. This performance sets the stage for a potential earnings turnaround even...

Earlier this week, Harmony Biosciences Holdings reported initial open-label extension data from its Phase 3 ARGUS trial of EPX-100 in Dravet syndrome, showing around a 50% median reduction in motor seizure frequency and generally good long-term tolerability. The emerging benefit-risk profile of EPX-100, including multi-year safety data and meaningful seizure reduction in a hard-to-treat population, could meaningfully enhance Harmony’s rare epilepsy portfolio if future results align with...

ConocoPhillips (COP) just delivered a Q3 2025 beat, lifting full year production guidance while trimming operating cost expectations, even as Wall Street stays cautious about oversupply risks and choppy geopolitics in the oil market. See our latest analysis for ConocoPhillips. Despite the Q3 beat and the Marathon Oil integration story, ConocoPhillips’ 1 month share price return of 7.26% sits against a weaker year to date share price return of minus 4.54%, while its 5 year total shareholder...

If you are wondering whether Teleflex at around $126 is a bargain or a value trap, you are not alone. This article is going to unpack exactly what the market might be missing. The stock has bounced 5.3% over the last week and 13.8% over the last month, even though it is still down 29.1% year to date and 28.8% over the past year. This pattern often signals that investors are rethinking the balance between risk and reward. Recent coverage has focused on Teleflex sharpening its portfolio around...

Jazz Pharmaceuticals recently announced that multiple new data sets on its epilepsy drug Epidiolex and oncology candidate Ziihera were accepted for presentation at major medical meetings, including late-breaking clinical and real-world evidence results shared at the American Epilepsy Society 2025 conference. This wave of fresh data, spanning seizure control, treatment patterns, real-world outcomes, and potential synergy with other therapies, strengthens the clinical profile of two of Jazz’s...

If you are wondering whether Uber Technologies remains a smart buy after its huge run, or whether the easy money has already been made, this is the right place to unpack what the market is really pricing in. Despite a recent pullback, with the stock down 6.8% over the last week and 9.0% over the past month, Uber is still up 34.7% year to date and 42.0% over the last year, with a 227.7% gain over three years. Much of this move has been associated with growing confidence in Uber's ability to...

Wondering if Luckin Coffee is still a bargain after its comeback story, or if you are arriving late to the party? This breakdown is designed to help you decide whether the current share price makes sense. The stock has cooled off a bit in the short term, slipping about 1.4% over the last week and 7.0% over the last month, but it is still up roughly 31.5% year to date and an impressive 50.6% over the last year. A massive 275.8% gain over five years hints at how powerful sentiment swings can...

Recent performance puts AtriCure in focus AtriCure (ATRC) has quietly put together a strong run, with the stock up around 28% over the past month and roughly 39% year to date, drawing fresh attention to its growth story. See our latest analysis for AtriCure. That momentum is not just a one week pop. AtriCure’s recent double digit 1 month share price return has helped turn a modest multi year total shareholder return into a far more convincing uptrend as investors warm to its growth...

Energy Fuels (UUUU) has quietly transformed from a niche uranium player into a broader critical minerals story, and the stock’s wild swings over the past year have many investors rethinking its long term risk reward. See our latest analysis for Energy Fuels. After a huge run up earlier in the year, the recent pullback, including a 7.9 percent 1 day share price return decline, looks more like a pause than a reversal when you zoom out to its 156.5 percent year to date share price return and 144...

Valaris (VAL) just locked in a multi year, $300 million drilling contract with Shell offshore Brazil, a long duration deal that immediately fattens its backlog and clarifies demand visibility into 2027. See our latest analysis for Valaris. The Shell win lands just as sentiment has cooled, with the 1 day share price return down 6.83 percent and the 7 day share price return off 9.68 percent. Even so, the year to date share price return still sits above 20 percent and the 1 year total...

Pagaya Technologies recently closed PAID 2025-8, a AAA-rated US$500 million asset-backed securitization backed by consumer loans originated on its network, bringing its year-to-date ABS funding for personal loans to about US$5.40 billion. The deal, which attracted broad investor participation, highlights ongoing confidence in Pagaya’s AI-driven credit platform and its ability to consistently secure large-scale funding in the securitization market. Next, we’ll explore how this latest US$500...

In December 2025, McDonald’s drew heavy customer traffic with its limited-time Grinch Meal while also rolling out plans to tighten value-focused pricing standards for franchisees from January 2026. Together, the viral success of the Grinch promotion and a renewed push for consistent value highlight how McDonald’s is leaning on marketing and pricing discipline to keep budget-conscious diners engaged. We’ll now explore how McDonald’s sell-out Grinch promotion and sharpened value standards...

In recent weeks, Axon Enterprise has secured multi‑million‑dollar public safety technology contracts, including a US$14.3 million, nine‑year package with Rialto and a US$5.8 million agreement with Evanston for body cameras, fleet cameras, TASER upgrades, drones, and its AI‑enabled Real‑Time Crime Center platform. These wins highlight how Axon’s expanding AI, drone, and software ecosystem is becoming embedded in long‑term police technology modernization plans, even as communities debate...

Wondering if Apple is still worth buying at these levels, or if most of the upside is already priced in? You are not alone. This article will walk through what the current share price really implies. Apple has delivered a 14.1% gain year to date and is up 12.7% over the last year. The last week was basically flat at around a 0.2% dip, and the past month saw a modest 1.8% rise, keeping it firmly in long-term compounder territory with a 110.0% 3 year and 125.7% 5 year return profile. Recent...

If you are wondering whether eToro Group is a beaten down opportunity or a value trap at current levels, you are not alone. This article will walk through what the numbers are really saying about the stock. Despite solid brand recognition, the share price has had a rough ride recently, falling about 11.8% over the last week, 8.2% over the past month, and 43.4% year to date. This naturally raises questions about whether the risk reward balance has shifted. Recent headlines have focused on...

Wondering if Photronics is still a smart buy after its big run, or if you are late to the party? This breakdown will help you decide whether the current price really matches the company’s underlying value. The stock has been on a tear, jumping about 50.4% over the last week, 61.7% over the past month, and delivering 51.2% year to date, with longer term returns of 37.1% over 1 year, 110.9% over 3 years, and 224.9% over 5 years. Recent market attention has centered on Photronics as investors...

In June 2025, Revolution Medicines announced that the US FDA granted Breakthrough Therapy Designation to its oral RAS(ON) inhibitor daraxonrasib for previously treated metastatic pancreatic ductal adenocarcinoma patients with KRAS G12 mutations, based on emerging clinical data. This designation not only aims to speed development and review, but also highlights Revolution Medicines’ specialized position in tackling RAS-driven cancers, an area with significant unmet need. Next, we’ll explore...

National Beverage (FIZZ) just posted Q2 2026 results with revenue of $288 million and basic EPS of $0.50, alongside net income of about $46 million that keeps profitability in focus for shareholders. The company has seen quarterly revenue move from $291 million in Q2 2025 to $288 million this quarter, while basic EPS has hovered around the $0.48 to $0.50 range over that span, giving investors a fairly consistent read on earnings power. With net income holding in the mid $40 million range and...

In recent months, Unity Software reversed its controversial runtime fee, returned to a subscription billing model, delivered stronger-than-expected quarterly earnings, and attracted a series of analyst upgrades and fresh interest in its AI-powered advertising and real-time 3D tools. At the same time, investors are weighing this renewed enthusiasm against issues like past share dilution, ongoing operating losses, and softer billings, creating a nuanced picture of Unity’s progress and...

Chewy (CHWY) just delivered a stronger than expected third quarter, then followed it up by tightening and slightly raising its full year outlook, signaling more confidence in its growth and efficiency story. See our latest analysis for Chewy. Even with the upgraded guidance and recurring revenue momentum, Chewy’s recent 90 day share price return of negative 5.54 percent and year to date share price return of negative 3.34 percent show that sentiment is still resetting after earlier optimism,...

Wondering if Intel at around $37.81 is still a smart buy after its big run, or if the easy money has already been made? Let us cut through the noise and focus on what the numbers actually say about value. Despite dropping 8.7% over the last week and slipping 0.2% over the past month, Intel is still up an impressive 87.0% year to date and 85.9% over the last year, while its 3 year gain of 45.7% contrasts with a 5 year decline of 11.9%. Much of this volatility has been driven by shifting...

Why Amicus Therapeutics Stock Is Back on Investors Radar Amicus Therapeutics (FOLD) has quietly put together a strong rebound, with the stock up roughly 12% this month and more than 32% over the past 3 months, drawing fresh attention. See our latest analysis for Amicus Therapeutics. That recent 6.57% one day share price move, on top of a 30 day share price return of 12%, has pushed Amicus back toward the upper end of its yearly range. This suggests momentum is rebuilding even though the five...